A Study Comparing the Long Term Safety of Entyvio (Vedolizumab) to Other Biologic Agents in Patients with Ulcerative Colitis or Crohn's Disease

Overview

About this study

The purpose of this study is to assess the long-term safety of vedolizumab versus other biologic agents in participants with Ulcerative Colitis or Crohn's Disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

Signed informed consent, by the participant or a legally acceptable representative
Aged at least 18 years
Initiating vedolizumab or another biologic agent for ulcerative colitis or crohn's disease
Signed release form by the participant or a legally acceptable representative permitting abstraction of the participant's medical records at Baseline and during participation in the study

Exclusion Criteria

Enrolled in a clinical trial in which treatment for crohn's disease or ulcerative colitis is managed through a protocol
Prior treatment with vedolizumab
Any reason that, in the Investigator's opinion, makes the participant unsuitable to participate in this study

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Edward Loftus, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Edward Loftus, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials